Quarterly report pursuant to Section 13 or 15(d)

Non-Controlling Interests (Schedule of Non-Controlling Interests in Consolidated Entities) (Details)

v3.23.3
Non-Controlling Interests (Schedule of Non-Controlling Interests in Consolidated Entities) (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Noncontrolling Interest [Line Items]          
Net loss attributable to non-controlling interests $ (5,679) $ (30,549) $ (73,812) $ (96,841) $ (127,338)
Non-controlling interests in consolidated entities (29,917)   (29,917)   8,304
Aevitas          
Noncontrolling Interest [Line Items]          
Net loss attributable to non-controlling interests         (425)
Non-controlling interests in consolidated entities         $ (5,753)
Non-controlling ownership         45.20%
Avenue          
Noncontrolling Interest [Line Items]          
Net loss attributable to non-controlling interests     (9,298)   $ (2,355)
Non-controlling interests in consolidated entities $ (3,346)   $ (3,346)   $ 3,054
Non-controlling ownership 88.30%   88.30%   89.90%
Baergic          
Noncontrolling Interest [Line Items]          
Net loss attributable to non-controlling interests         $ (113)
Cellvation          
Noncontrolling Interest [Line Items]          
Net loss attributable to non-controlling interests     $ (25)   (102)
Non-controlling interests in consolidated entities $ (1,949)   $ (1,949)   $ (1,791)
Non-controlling ownership 21.30%   21.30%   21.30%
Checkpoint          
Noncontrolling Interest [Line Items]          
Net loss attributable to non-controlling interests     $ (26,625)   $ (48,406)
Non-controlling interests in consolidated entities $ (16,966)   $ (16,966)   $ (16,008)
Non-controlling ownership 89.10%   89.10%   82.20%
Coronado SO          
Noncontrolling Interest [Line Items]          
Net loss attributable to non-controlling interests     $ 0   $ 0
Non-controlling interests in consolidated entities $ (290)   $ (290)   $ (291)
Non-controlling ownership 13.00%   13.00%   13.00%
Cyprium          
Noncontrolling Interest [Line Items]          
Net loss attributable to non-controlling interests     $ (1,335)   $ (1,173)
Non-controlling interests in consolidated entities $ (5,491)   $ (5,491)   $ (3,817)
Non-controlling ownership 28.30%   28.30%   29.00%
Helocyte          
Noncontrolling Interest [Line Items]          
Net loss attributable to non-controlling interests     $ 45   $ (122)
Non-controlling interests in consolidated entities $ (5,994)   $ (5,994)   $ (5,900)
Non-controlling ownership 17.50%   17.50%   17.90%
JMC          
Noncontrolling Interest [Line Items]          
Net loss attributable to non-controlling interests     $ (515)   $ (12,458)
Non-controlling interests in consolidated entities $ 8,035   $ 8,035   $ 7,429
Non-controlling ownership 46.20%   46.20%   43.70%
Mustang          
Noncontrolling Interest [Line Items]          
Net loss attributable to non-controlling interests     $ (34,026)   $ (60,821)
Non-controlling interests in consolidated entities $ 3,184   $ 3,184   $ 37,640
Non-controlling ownership 79.40%   79.40%   81.30%
Oncogenuity          
Noncontrolling Interest [Line Items]          
Net loss attributable to non-controlling interests     $ (11)   $ (111)
Non-controlling interests in consolidated entities $ (1,721)   $ (1,721)   $ (1,575)
Non-controlling ownership 27.00%   27.00%   27.40%
Tamid          
Noncontrolling Interest [Line Items]          
Net loss attributable to non-controlling interests         $ (1)
Non-controlling interests in consolidated entities         $ (776)
Non-controlling ownership         22.80%
Urica          
Noncontrolling Interest [Line Items]          
Net loss attributable to non-controlling interests     $ (2,022)   $ (1,251)
Non-controlling interests in consolidated entities $ (5,379)   $ (5,379)   $ (3,908)
Non-controlling ownership 33.00%   33.00%   40.20%